Valtropin
Somatropin biosimilar developed by BioPartners (LG Life Sciences). Reference product Genotropin (Omnitrope's reference); also Norditropin, Humatrope, Saizen.
Brands by market: Valtropin (EU, withdrawn) · Commercial partner or holder: BioPartners · Company profile
FDANot listed
EMAWithdrawn
MHRANot listed
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Not yet approved in any of the 7 markets
Connections
About Valtropin
Valtropin was a somatropin developed by LG Life Sciences and approved in Europe in April 2006 through BioPartners, days after Omnitrope. It was withdrawn in 2012 and never gained a significant market.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Valtropin
European Medicines Agency and European CommissionWithdrawnBrand
Valtropin
Holder or applicant
BioPartners GmbH
Pathway
Centralised (Article 10(4))
Approved
Apr 2006
Application or permission
EMEA/H/C/000602
Withdrawn
May 2012
Presentations
see SmPC
Source
S017 (EMA) · checked Sep 2026
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Same developer, other molecules
Other biosimilars in the Atlas developed by BioPartners: Alpheon.
Chronology
- EMAMay 2012Valtropin authorisation withdrawn
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning somatropin biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.